A common painkiller is sending a steady stream of New Zealand children to the liver transplant waiting list and now a new study is hoped to stem the tide
Douglas Pharmaceuticals is heralding early results of its trial on using ketamine to treat depression as possibly the most significant step in the field for 25 years
The Food and Drug Administration set off a firestorm of debate when it approved a new drug, aducanumab, for Alzheimer’s disease via an accelerated approval pathway
Douglas Pharmaceuticals is heralding early results of its trial on using ketamine to treat depression as possibly the most significant step in the field for 25 years
New Zealand based Douglas Pharmaceuticals Ltd is pleased to announce that a majority of patients with Treatment Resistant Depression experienced rapid relief of their symptoms when treated with R-107 (extended-release oral dose of ketamine) in a Phase 2 study
A study whose lead author is a Te Herenga Waka—Victoria University of Wellington epidemiologist has found the Pfizer-BioNTech COVID-19 vaccine used in New Zealand is not associated with a condition that affects the blood known as idiopathic thrombocytopenic purpura (ITP) and other clotting and bleeding events
Collaboration is key to boosting maternal vaccination rates to protect mothers and babies from life-threating illnesses, VIP study team principal investigator Natalie Gauld says
In a world first, New Zealand scientists have shown that vitamin C, in high-dose infusions, infiltrates cancer tumours. Fiona Cassie finds out what this means for the unproven, but popular, complementary therapy
This month, the Ngā Kaitiaki o Te Puna Rongoā o Aotearoa – Māori Pharmacists’ Association will begin research into how Māori can receive equitable access to minor ailments medicines
Aotearoa achieved a major milestone in sexual and reproductive health and rights with the decriminalisation of abortion, but a University of Otago academic argues abortion care is still not being provided within the full extent of the law
Academic pharmacist Nataly Martini provides key information on Helicobacter pylori pathophysiology, diagnosis and evidence-based treatment strategies to enhance patient outcomes